Private equity firm Behrman Capital made a significant investment in The Emmes Corporation, a leading contract research organization that partners with government, private foundation, and commercial clients to develop treatments for diseases and disorders impacting public health. Financial terms were not disclosed. Grant G. Behrman, Managing Partner of Behrman Capital, said, "Emmes has built a strong and enduring heritage as a trusted and collaborative research partner. The Company is well positioned for growth in the near- and long-term, across a number of therapeutic areas of focus including infectious disease, oncology and ophthalmology. We look forward to partnering with Anne, Sal, and Emmes' world-class team to increase the scope and scale of the business through organic initiatives and accretive acquisitions."